Independent Review of Indonesian Phase 3 R327G Trial Data

• Blinded data review shows strong efficacy of R327G
• Independent Data Monitoring Committee to review unblinded data
• Patient recruitment and dosing ongoing during the review process

Recce Pharmaceuticals Ltd announced that a review of blinded data from its Phase 3 trial of R327G, a topical gel for treating diabetic foot ulcers, shows strong efficacy and a positive safety profile. The Independent Data Monitoring Committee will review unblinded data and provide recommendations after its meeting, expected in mid-November. The trial, which includes 90 patients, continues during the review process. R327G is part of Recce's pipeline of synthetic anti-infectives designed to combat antibiotic-resistant superbugs.

Recce Pharmaceuticals anticipates receiving recommendations from the Data Monitoring Committee in mid-November, which may influence the progression of the trial and potential regulatory submissions.